-
OpenAI Releases Research Preview of ‘gpt-oss-safeguard’: Two Open-Weight Reasoning Models for Safety Classification Tasks
OpenAI Releases Research Preview of ‘gpt-oss-safeguard’: Two Open-Weight Reasoning Models for Safety Classification Tasks Understanding the Target Audience The target audience for this release primarily includes: AI Developers and Researchers: They seek advanced tools for effective moderation and safety in AI applications, focusing on customization and adaptability. Business Leaders: These individuals are interested in integrating… →
-
A randomized controlled trial of electronic balance assistant combined with pharmacotherapy for vestibular rehabilitation in patients with acute peripheral vestibular injury
Objective: To evaluate the effect of an electronic balance aid in balance rehabilitation training for patients with acute peripheral vestibular injury by comparing the outcomes of medication-only treatment and medication combined with vestibular rehabilitation using an electronic balance aid. Methods: This was a randomized controlled trial. The study subjects included 98 patients (40 males and… →
-
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
BACKGROUND: Abemaciclib, a potent CDK4 and CDK6 inhibitor, has shown antitumour activity in prostate cancer models and in patients with metastatic castration-resistant prostate cancer (mCRPC) who have been heavily treated. We aimed to evaluate the safety and efficacy of abemaciclib in combination with abiraterone in patients with mCRPC. →
-
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
BACKGROUND: Patritumab deruxtecan (HER3-DXd) is a novel antibody-drug conjugate targeting HER3, which is overexpressed in CNS metastases of metastatic breast cancer. We aimed to evaluate the activity and safety of HER3-DXd in patients with metastatic breast cancer and brain metastases that are newly diagnosed or progressing after local therapy. →
-
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
BACKGROUND: Patritumab deruxtecan (HER3-DXd) is a novel antibody-drug conjugate targeting HER3, which is overexpressed in CNS metastases of advanced non-small-cell lung cancer (NSCLC). We aimed to evaluate the activity and safety of HER3-DXd in patients with advanced NSCLC and newly diagnosed brain metastases or brain metastases progressing after local therapy. →
-
How to Design an Autonomous Multi-Agent Data and Infrastructure Strategy System Using Lightweight Qwen Models for Efficient Pipeline Intelligence?
How to Design an Autonomous Multi-Agent Data and Infrastructure Strategy System Using Lightweight Qwen Models for Efficient Pipeline Intelligence How to Design an Autonomous Multi-Agent Data and Infrastructure Strategy System Using Lightweight Qwen Models for Efficient Pipeline Intelligence This tutorial outlines the development of an Agentic Data and Infrastructure Strategy system utilizing the lightweight Qwen2.5-0.5B-Instruct… →
-
Five Traits of Tech-Driven CEOs
Fabien Gilbert/Ikon Images When the chief executive of a global retailer recently faced mounting pressure from online rivals, he chose an unconventional response. Instead of relying on the playbook that once powered the company’s growth, he immersed himself in emerging technologies. He sought advice from outside experts, hired executives with digital expertise, and built new… →
-
Do We Need Humanlike AI? Experts Say It Depends
For the fourth year in a row, MIT Sloan Management Review and Boston Consulting Group (BCG) have assembled an international panel of AI experts that includes academics and practitioners to help us understand how responsible artificial intelligence (RAI) is being implemented across organizations worldwide. In spring 2025, we also fielded a global executive survey yielding… →
-
The order of completing MDP and D12 does not affect the breathlessness responses: A randomised controlled trial
BackgroundBreathlessness is a common and distressing symptom across a wide range of medical conditions. Different aspects (dimensions) of breathlessness can be assessed using the Multidimensional Dyspnoea Profile (MDP) and Dyspnoea-12 (D12) questionnaires. We aimed to examine whether the order of completing MDP and D12 affects the breathlessness responses in people with cardiorespiratory disease.MethodsThis was a… →
-
Ant Group Releases Ling 2.0: A Reasoning-First MoE Language Model Series Built on the Principle that Each Activation Enhances Reasoning Capability
«`html Ant Group Releases Ling 2.0: A Reasoning-First MoE Language Model Series The target audience for Ling 2.0 primarily includes AI researchers, data scientists, and business leaders in technology sectors who are interested in advanced language models and their applications in enterprise solutions. These individuals often face pain points such as the need for more… →